Calaspargase Pegol

證據等級: L5

預測適應症: 4 個

Calaspargase Pegol: From Acute Lymphoblastic Leukemia to Insomnia

One-Sentence Summary

Calaspargase pegol is a PEGylated asparaginase used in multi-agent chemotherapy for Acute Lymphoblastic Leukemia (ALL), acting primarily by depleting circulating asparagine to starve protein synthesis-dependent malignant lymphoblasts. The TxGNN model predicts it may be effective for Insomnia with a score of 99.80%, yet no clinical trials and no published literature support this direction — the prediction is assessed as likely graph neural network noise rather than a genuine biological signal. This report covers all four top-ranked predictions, all of which are recommended as Hold.

Quick Overview

Item	Content
Original Indication	Acute Lymphoblastic Leukemia (ALL) — internationally approved; no licenses found in this system
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.80%
Evidence Level	L5
US Market Status	Not marketed (0 license records)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Based on mechanistic analysis, this prediction is not biologically plausible. Detailed MOA data is not available in the current evidence pack, but calaspargase pegol is well characterized as an enzymatic asparaginase — it depletes serum asparagine (Asn) to block protein synthesis in Asn-dependent tumor cells (lymphoblasts). This is the defining pharmacological mechanism of the asparaginase drug class.

Sleep regulation operates through entirely distinct neurobiological pathways: adenosine accumulation, melatonin synthesis from tryptophan, GABAergic inhibitory tone, and circadian transcription factor cycling. None of these pathways share a meaningful intersection with asparagine depletion. There is no published hypothesis, preclinical model, or mechanistic rationale connecting asparaginase activity to insomnia treatment.

The TxGNN score of 99.80% for insomnia is therefore suspected to reflect cross-domain graph neighborhood noise — an artifact of the graph neural network picking up distant, non-biological co-occurrence edges — rather than a real repurposing opportunity. This interpretation is strongly supported by the complete absence of any clinical trial or literature evidence, and by the systematic false-positive pattern observed across all four top-ranked predictions (see Conclusion section).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No license records are available for calaspargase pegol in this system (0 NDAs, market status: not marketed).

Note for Review Teams: Calaspargase pegol (brand name Asparlas®) received FDA approval in December 2018 (NDA 761102) for use as a component of multi-agent chemotherapy for ALL in pediatric and young adult patients (≥1 month to <22 years). If this record shows zero licenses, it may indicate a data pipeline gap rather than a true absence of regulatory approval. Verification against the FDA Orange Book is recommended before concluding the drug is unapproved.

Cytotoxicity

Calaspargase pegol is an antineoplastic agent (asparaginase class) and requires the following assessment:

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Asparaginase class (enzymatic depletion of circulating L-asparagine)
Myelosuppression Risk	Low (myelosuppression is not a primary class toxicity; bone marrow is not the main target organ)
Emetogenicity Classification	Low
Monitoring Items	Coagulation panel (PT, aPTT, fibrinogen, antithrombin III), liver function (ALT, AST, total bilirubin, albumin), pancreatic enzymes (amylase, lipase), blood glucose, CBC with differential
Handling Protection	Must follow cytotoxic drug handling regulations; anaphylaxis risk requires emergency resuscitation equipment available at the bedside during every administration

Class-effect safety concerns (for clinical reference, pending formal label data): hypersensitivity/anaphylaxis; acute pancreatitis; coagulopathy (both thrombotic and hemorrhagic); hepatotoxicity; hyperglycemia. Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: All four TxGNN-predicted indications for calaspargase pegol lack any supporting clinical or literature evidence (all L5), and mechanistic analysis identifies two distinct false-positive patterns that explain the high model scores:

Rank	Predicted Indication	TxGNN Score	False-Positive Pattern
1	Insomnia	99.80%	Cross-domain graph noise — no mechanistic bridge between asparagine depletion and sleep regulation
2	Factor V excess with spontaneous thrombosis	99.25%	ADR misread as therapeutic signal — asparaginase depletes coagulation proteins (adverse effect), not Factor V specifically
3	Heparin cofactor 2 deficiency	99.24%	Mechanism direction reversed — asparaginase suppresses HCII synthesis, worsening not treating HCII deficiency
4	Antithrombin deficiency type 2	99.21%	Strongest ADR-as-treatment false positive — AT-III depletion is a well-documented severe adverse effect of asparaginase therapy; using this drug to treat AT deficiency would directly aggravate the condition

Predictions 2–4 represent a particularly important failure mode: the knowledge graph encodes strong asparaginase–coagulation edges derived from adverse drug reaction relationships, but the GNN treats them as potential therapeutic edges. This is a known structural limitation of KG-based drug repurposing models.

To proceed, the following is needed:

Verify US market status against the FDA Orange Book (possible data pipeline gap flagged above)
Retrieve complete MOA data from DrugBank API (Data Gap DG002) to formally document asparagine depletion as the primary mechanism
Flag this candidate as a confirmed false-positive case study for TxGNN model calibration — the ADR-edge misclassification pattern (Ranks 2–4) is reproducible and worth reporting to the model development team
No further evidence collection for the insomnia indication is warranted at this time; resources should be redirected to higher-priority candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.